We came across a bullish thesis on Biohaven Ltd. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on BHVN. Biohaven Ltd.'s share was trading at $11.54 as of February 18th. 25 Best Work-Life Balance Jobs to Enjoy Life Photographee.eu/Shutterstock.com Biohaven Ltd. is a clinical-stage biotechnology company targeting large global markets with significant unmet needs across neurology, immunology, and oncology, with lead programs such as its Kv7 activator franchise rep ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna.Looking at options history for Moderna (NASDAQ:MRNA) we detected 14 trades.If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 42% with bearish.From the overall spotted trades, 5 are puts, for a total amount of $180,802 and 9, calls, for a total amount of $512,400.Projected Price TargetsAnalyzing the Volume and Open Interest in these cont ...

Key TakeawaysModerna (MRNA) received a positive CHMP opinion for its mCOMBRIAX vaccine, the world’s first combination flu and COVID-19 shot recommended for authorization.Blackstone (BX) and Brookfield (BN) have emerged as lead bidders for a €8 billion unit of Volkswagen (VOW3), highlighting intense private equity interest in industrial divestments.Kazakhstan is significantly shifting its energy logistics, targeting 2.5 million tons of oil exports to Germany in 2026 while maintaining a 65 million ton flow vi ...

Group 1 - The recommendation from regulators facilitates the approval process for the shot in the European Union [1] - The company is currently under scrutiny in the United States [1]

Group 1 - The European Medicines Agency has recommended granting marketing authorization for Moderna's mCombriax, making it the first combined vaccine for COVID-19 and seasonal influenza for individuals aged 50 and older [1] - The vaccine utilizes messenger RNA technology, which has been pivotal in the development of COVID-19 vaccines [1] Group 2 - The approval of mCombriax represents a significant advancement in public health, potentially simplifying vaccination processes for older populations [1] - This development may enhance Moderna's market position and revenue potential in the vaccine sector [1]

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals Earlier this month, the U.S. Food and Drug Administration initially refused to review rival Moderna's (MRNA.O), opens new tab mRNA-based flu vaccine, then reversed course a week later after the company amended its application. The biotech now expects 2026 adjusted revenue of $230 million to $270 million, up from its prio ...

Vaxart (NasdaqCM:VXRT) FY Conference February 25, 2026 04:00 PM ET Company ParticipantsCheng Li - Director of Biotech Equity ResearchJames F. Cummings - Chief Medical OfficerSteven Lo - President and CEOCheng LiHello, welcome to Oppenheimer's 36th Annual Healthcare Conference. I am Cheng Li, one of the biotech analysts here at Oppenheimer, and it's a pleasure to welcome you to our next company, Vaxart. It's my honor to introduce Steven Lo, CEO, and James Cummings, CMO at Vaxart. We want to leave probably a ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.Looking at options history for Moderna (NASDAQ:MRNA) we detected 22 trades.If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 36% with bearish.From the overall spotted trades, 4 are puts, for a total amount of $774,679 and 18, calls, for a total amount of $1,215,014.What's The Price Target?Taking into account the Volume and Open Interest ...

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost February 23, 20268:15 PM UTCUpdated ago By Ahmed Aboulenein U.S. Food and Drug Administration Commissioner Marty Makary speaks during a press conference at the Department of Health and Human Services in Washington, D.C., U.S., November 10, 2025.... Purchase Licensing Rights, opens new tab Read ...

Group 1: Laffont's Investment Strategy - Billionaire Philippe Laffont, founder of Coatue Management, oversees $39 billion in 13F securities, primarily investing in technology stocks, with Taiwan Semiconductor Manufacturing as his largest holding at over 6.5% of his portfolio [1] - In the fourth quarter of the previous year, Laffont sold his entire position in CoreWeave, which had been a significant AI stock with triple-digit revenue growth [2][9] - Laffont's recent investment in Moderna, a biotech stock that has struggled but saw a nearly 50% increase in January, indicates a shift towards potential growth opportunities [3][12] Group 2: CoreWeave and Moderna - CoreWeave, which Laffont sold, had made up more than 2.2% of his portfolio and had seen an 80% increase since its IPO [8][9] - Moderna, which Laffont purchased 200,000 shares of, represents a very small position at 0.01% of his portfolio, but the company is focusing on long-term success through cost-cutting and expanding its vaccine offerings [10][11] - Moderna's stock has lost over 70% in the past three years, but its pipeline includes candidates in late-stage development, suggesting potential for recovery and growth in the future [10][14]